ES2795450T3 - Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos - Google Patents
Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos Download PDFInfo
- Publication number
- ES2795450T3 ES2795450T3 ES13837402T ES13837402T ES2795450T3 ES 2795450 T3 ES2795450 T3 ES 2795450T3 ES 13837402 T ES13837402 T ES 13837402T ES 13837402 T ES13837402 T ES 13837402T ES 2795450 T3 ES2795450 T3 ES 2795450T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- temperature
- batch
- less
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702137P | 2012-09-17 | 2012-09-17 | |
| US201361790432P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/060177 WO2014043706A1 (en) | 2012-09-17 | 2013-09-17 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2795450T3 true ES2795450T3 (es) | 2020-11-23 |
Family
ID=50278769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20157696T Active ES2907926T3 (es) | 2012-09-17 | 2013-09-17 | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| ES13837402T Active ES2795450T3 (es) | 2012-09-17 | 2013-09-17 | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20157696T Active ES2907926T3 (es) | 2012-09-17 | 2013-09-17 | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US9266861B2 (enExample) |
| EP (4) | EP3689853B1 (enExample) |
| JP (8) | JP6616688B2 (enExample) |
| KR (4) | KR20200023528A (enExample) |
| CN (2) | CN105008335B (enExample) |
| AR (1) | AR092872A1 (enExample) |
| AU (1) | AU2013315017C1 (enExample) |
| BR (2) | BR122021024202B1 (enExample) |
| CA (3) | CA2884481C (enExample) |
| DK (3) | DK2895466T3 (enExample) |
| ES (2) | ES2907926T3 (enExample) |
| FI (1) | FI4406594T3 (enExample) |
| IL (7) | IL314360B2 (enExample) |
| IN (1) | IN2015DN03133A (enExample) |
| MX (2) | MX395148B (enExample) |
| MY (1) | MY170520A (enExample) |
| NZ (2) | NZ739645A (enExample) |
| PT (1) | PT4406594T (enExample) |
| RU (2) | RU2018128393A (enExample) |
| SG (3) | SG11201501907YA (enExample) |
| TW (4) | TWI652260B (enExample) |
| WO (1) | WO2014043706A1 (enExample) |
| ZA (1) | ZA201501795B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL314360B2 (en) | 2012-09-17 | 2025-09-01 | F Hoffmann La Roche Ltd | Method for the synthesis of thyroid hormone analogs and their polymorphs |
| KR20190109387A (ko) * | 2016-10-18 | 2019-09-25 | 마드리갈 파마슈티칼스, 인크. | Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법 |
| US11485729B2 (en) | 2018-01-23 | 2022-11-01 | Shenzhen Targetrx, Inc. | Substituted pyridazinone compound |
| CN111801324B (zh) | 2018-06-12 | 2021-10-22 | 四川海思科制药有限公司 | 甲状腺激素受体激动剂及其用途 |
| US20210292304A1 (en) * | 2018-06-22 | 2021-09-23 | Hinova Pharmaceuticals Inc. | Deuterated mgl-3196 compound and use thereof |
| AR115666A1 (es) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| KR20210076932A (ko) | 2018-10-12 | 2021-06-24 | 인벤티스바이오 컴퍼니 리미티드 | 갑상선 호르몬 수용체 작용제 |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN113474335B (zh) * | 2019-02-21 | 2024-12-03 | 南京瑞捷医药科技有限公司 | 化合物及其作为甲状腺激素受体激动剂的用途 |
| KR20220017917A (ko) * | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| TW202108556A (zh) * | 2019-05-10 | 2021-03-01 | 大陸商深圳微芯生物科技股份有限公司 | 一種噠嗪酮衍生物及其應用 |
| WO2020239076A1 (zh) * | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| CN112442013B (zh) * | 2019-09-04 | 2022-07-26 | 广东东阳光药业有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN112707892A (zh) * | 2019-10-24 | 2021-04-27 | 苏州泽璟生物制药股份有限公司 | 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物 |
| JP7574292B2 (ja) | 2019-11-26 | 2024-10-28 | 昆薬集団股▲フン▼有限公司 | １，２，４－トリアジン－３，５－ジオン系化合物およびその製造方法と応用 |
| WO2021121210A1 (zh) * | 2019-12-16 | 2021-06-24 | 江苏恒瑞医药股份有限公司 | 并环类衍生物、其制备方法及其在医药上的应用 |
| WO2021129465A1 (zh) | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| CN116056709A (zh) * | 2020-08-27 | 2023-05-02 | 益方生物科技(上海)股份有限公司 | 哒嗪酮化合物 |
| EP4286377A4 (en) * | 2020-09-10 | 2024-10-09 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF RESMETIROM, ITS PREPARATION METHOD AND ITS USE |
| CA3195789A1 (en) | 2020-10-19 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| CN114437042A (zh) * | 2020-11-03 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 酞嗪类化合物的晶型及其制备方法 |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| TW202245775A (zh) | 2021-02-01 | 2022-12-01 | 美商瑪德瑞高製藥公司 | 用於治療肝病症或脂質病症之瑞舒伐他汀（Ｒｏｓｕｖａｓｔａｔｉｎ）和瑞司美替隆（Ｒｅｓｍｅｔｉｒｏｍ）的治療組合 |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法 |
| WO2023049491A1 (en) | 2021-09-27 | 2023-03-30 | Madrigal Pharmaceuticals, Inc. | Resmetirom for reducing liver volume |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4568664A1 (en) | 2023-04-07 | 2025-06-18 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| CN116768802B (zh) * | 2023-05-25 | 2025-11-21 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗的合成方法 |
| US20240423992A1 (en) | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | Biomarkers for treating liver disorders with thr-b agonists and related uses |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| CN117263870A (zh) * | 2023-09-21 | 2023-12-22 | 江西同和药业股份有限公司 | 一种Resmetirom关键中间体III的制备方法 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025164161A1 (ja) * | 2024-01-29 | 2025-08-07 | シオノギファーマ株式会社 | カンナビジオールの溶媒和物及びカンナビジオールの精製方法 |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025191457A1 (en) * | 2024-03-13 | 2025-09-18 | Morepen Laboratories Limited | Process for the preparation of pyridazinone derivative |
| CN119306670A (zh) * | 2024-10-12 | 2025-01-14 | 北京海美桐医药科技有限公司 | 瑞司美替罗中间体、其合成方法和瑞司美替罗的合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) * | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
| BRPI0407022A (pt) * | 2003-01-28 | 2006-01-10 | Academisch Ziekenhuis Leiden | Composto peptìdico com afinidade para toxinas bacterianas e fúngicas, método para a preparação do mesmo, uso de um composto, composição farmacêutica, sequência de ácido nucleico, e, composição de liberação de genes |
| CA2518823A1 (en) | 2003-03-24 | 2004-10-07 | F.Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| ITRM20030363A1 (it) | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| US7498315B2 (en) | 2004-06-01 | 2009-03-03 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| US7807647B2 (en) * | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| ES2441718T3 (es) | 2004-11-02 | 2014-02-06 | Northwestern University | Compuestos de piridazina, composiciones y métodos |
| JP5000649B2 (ja) | 2005-07-21 | 2012-08-15 | エフ．ホフマン−ラ ロシュ アーゲー | 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体 |
| CN101772487B (zh) * | 2007-06-06 | 2014-01-22 | 托伦特药物有限公司 | 甲状腺类化合物 |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| IL314360B2 (en) | 2012-09-17 | 2025-09-01 | F Hoffmann La Roche Ltd | Method for the synthesis of thyroid hormone analogs and their polymorphs |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| CN106132969A (zh) | 2014-02-14 | 2016-11-16 | 森普拉制药公司 | 用于治疗糖尿病和肝病的组合物和方法 |
| KR20190109387A (ko) | 2016-10-18 | 2019-09-25 | 마드리갈 파마슈티칼스, 인크. | Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법 |
| CN111801324B (zh) | 2018-06-12 | 2021-10-22 | 四川海思科制药有限公司 | 甲状腺激素受体激动剂及其用途 |
| AR115666A1 (es) | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| KR20210076932A (ko) | 2018-10-12 | 2021-06-24 | 인벤티스바이오 컴퍼니 리미티드 | 갑상선 호르몬 수용체 작용제 |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
-
2013
- 2013-09-17 IL IL314360A patent/IL314360B2/en unknown
- 2013-09-17 DK DK13837402.0T patent/DK2895466T3/da active
- 2013-09-17 KR KR1020207005528A patent/KR20200023528A/ko not_active Ceased
- 2013-09-17 BR BR122021024202-0A patent/BR122021024202B1/pt active IP Right Grant
- 2013-09-17 TW TW102133687A patent/TWI652260B/zh active
- 2013-09-17 TW TW110117935A patent/TWI804870B/zh active
- 2013-09-17 IL IL288133A patent/IL288133B2/en unknown
- 2013-09-17 WO PCT/US2013/060177 patent/WO2014043706A1/en not_active Ceased
- 2013-09-17 CA CA2884481A patent/CA2884481C/en active Active
- 2013-09-17 NZ NZ73964513A patent/NZ739645A/en unknown
- 2013-09-17 AU AU2013315017A patent/AU2013315017C1/en active Active
- 2013-09-17 BR BR112015005891A patent/BR112015005891A2/pt not_active Application Discontinuation
- 2013-09-17 FI FIEP24173563.8T patent/FI4406594T3/fi active
- 2013-09-17 CA CA3111317A patent/CA3111317C/en active Active
- 2013-09-17 CN CN201380059943.5A patent/CN105008335B/zh active Active
- 2013-09-17 EP EP20157696.4A patent/EP3689853B1/en active Active
- 2013-09-17 RU RU2018128393A patent/RU2018128393A/ru unknown
- 2013-09-17 TW TW108132827A patent/TWI755628B/zh active
- 2013-09-17 SG SG11201501907YA patent/SG11201501907YA/en unknown
- 2013-09-17 DK DK24173563.8T patent/DK4406594T3/da active
- 2013-09-17 ES ES20157696T patent/ES2907926T3/es active Active
- 2013-09-17 EP EP24173563.8A patent/EP4406594B1/en active Active
- 2013-09-17 KR KR1020157009807A patent/KR101966490B1/ko active Active
- 2013-09-17 CA CA3090070A patent/CA3090070C/en active Active
- 2013-09-17 IN IN3133DEN2015 patent/IN2015DN03133A/en unknown
- 2013-09-17 KR KR1020217019940A patent/KR102363776B1/ko active Active
- 2013-09-17 EP EP21209827.1A patent/EP4023641B1/en active Active
- 2013-09-17 KR KR1020187034908A patent/KR102138750B1/ko active Active
- 2013-09-17 SG SG10202006058QA patent/SG10202006058QA/en unknown
- 2013-09-17 IL IL320269A patent/IL320269A/en unknown
- 2013-09-17 DK DK20157696.4T patent/DK3689853T3/da active
- 2013-09-17 EP EP13837402.0A patent/EP2895466B1/en active Active
- 2013-09-17 PT PT241735638T patent/PT4406594T/pt unknown
- 2013-09-17 NZ NZ705827A patent/NZ705827A/en unknown
- 2013-09-17 JP JP2015532148A patent/JP6616688B2/ja active Active
- 2013-09-17 MX MX2018014924A patent/MX395148B/es unknown
- 2013-09-17 AR ARP130103332A patent/AR092872A1/es active IP Right Grant
- 2013-09-17 TW TW107137798A patent/TWI681957B/zh active
- 2013-09-17 ES ES13837402T patent/ES2795450T3/es active Active
- 2013-09-17 MY MYPI2015000591A patent/MY170520A/en unknown
- 2013-09-17 MX MX2015003418A patent/MX364661B/es active IP Right Grant
- 2013-09-17 SG SG10201705984XA patent/SG10201705984XA/en unknown
- 2013-09-17 CN CN201810077707.0A patent/CN108101851A/zh active Pending
- 2013-09-17 RU RU2015114327A patent/RU2668960C2/ru active
-
2015
- 2015-03-09 IL IL237628A patent/IL237628B/en active IP Right Grant
- 2015-03-16 ZA ZA2015/01795A patent/ZA201501795B/en unknown
- 2015-03-17 US US14/660,720 patent/US9266861B2/en active Active
-
2016
- 2016-02-17 US US15/046,213 patent/US9968612B2/en active Active
-
2017
- 2017-12-26 JP JP2017249107A patent/JP6532931B2/ja active Active
-
2018
- 2018-04-10 US US15/949,389 patent/US10376517B2/en active Active
- 2018-05-27 IL IL259610A patent/IL259610B/en active IP Right Grant
- 2018-11-20 JP JP2018217045A patent/JP6765408B2/ja active Active
-
2019
- 2019-02-25 IL IL265030A patent/IL265030B/en active IP Right Grant
- 2019-07-01 US US16/458,546 patent/US10894050B2/en active Active
- 2019-08-27 JP JP2019154299A patent/JP6899413B2/ja active Active
-
2020
- 2020-02-10 JP JP2020020343A patent/JP7038745B2/ja active Active
- 2020-06-15 IL IL275393A patent/IL275393B/en unknown
- 2020-12-11 US US17/118,706 patent/US11564926B2/en active Active
-
2022
- 2022-03-07 JP JP2022034154A patent/JP7436542B2/ja active Active
- 2022-12-15 US US18/066,677 patent/US20230210856A1/en not_active Abandoned
-
2023
- 2023-12-22 US US18/393,818 patent/US20240148742A1/en not_active Abandoned
- 2023-12-22 US US18/393,813 patent/US11986481B2/en active Active
-
2024
- 2024-02-07 JP JP2024016915A patent/JP2024056793A/ja active Pending
-
2025
- 2025-09-03 JP JP2025145966A patent/JP2025179154A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2795450T3 (es) | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos | |
| HK40113302B (en) | Thyroid hormone analogs | |
| HK40113302A (en) | Thyroid hormone analogs | |
| HK40077432B (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| HK40077432A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| HK40033715B (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| HK40033715A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| HK1212682B (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof |